<p>Johnson & Johnson has inked a licensing deal with Achillion Pharmaceuticals that could threaten Gilead Sciences market share in hepatitis C someday. Motley Fool's Michael Douglass and Todd Campbell dig into the details of this deal to see if Gilead Sciences investors should worry.</p>

Johnson & Johnson has inked a licensing deal with Achillion Pharmaceuticals that could threaten Gilead Sciences market share in hepatitis C someday. Motley Fool's Michael Douglass and Todd Campbell dig into the details of this deal to see if Gilead Sciences investors should worry.

<p>Johnson &amp; Johnson has inked a licensing deal with Achillion Pharmaceuticals that could threaten Gilead Sciences market share in hepatitis C someday. Motley Fool's Michael&nbsp;Douglass and Todd Campbell dig into the&nbsp;details of this&nbsp;deal to see if Gilead Sciences investors should worry.</p>

Healthcare: Johnson & Johnson Takes A Shot At Gilead Sciences

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.

Share Healthcare: Johnson & Johnson Takes A Shot At Gilead Sciences

Sign up to save your podcasts

Healthcare: Johnson & Johnson Takes A Shot At Gilead Sciences

Healthcare: Johnson & Johnson Takes A Shot At Gilead Sciences